A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates - PubMed (original) (raw)
A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates
J Cotropia et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul.
Abstract
A potential component that may be useful for passive immunotherapy for HIV-1 is human monoclonal antibodies (HumAbs) possessing potent anti-HIV-1 activity that is directed against conserved regions of the envelope glycoprotein. Such antibodies would, in principle, have the ability to neutralize diverse isolates of HIV-1. To develop such reagents, hybridomas were derived by initial Epstein Barr virus transformation of peripheral blood mononuclear cells (PBMCs) from an asymptomatic HIV-1 seropositive donor followed by fusion with heteromyelomas, and secreted anti-HIV-1 antibodies were further characterized. The specificity of one HumAb, designated as clone 3, was determined by enzyme-linked immunosorbent assay (ELISA) and Western blotting analyses that indicated reactivity to the transmembrane envelope glyco-protein gp41. Synthetic pentadecapeptides overlapping by 10 amino acids were utilized for epitope mapping of clone 3; a decapeptide GCSGKLICTT in the transmembrane gp41 was identified as the epitope. Clone 3 bound to SupT1 cells infected with HTLV-IIIB in fluorescent activated cell sorting analysis. In addition, in vitro biological assays demonstrated that clone 3 possessed neutralization reactivity against diverse laboratory isolates as well as an AZT-resistant isolate. Therefore, clone 3 reactivity defines a conserved neutralizable site on the HIV-1 transmembrane glycoprotein. Clone 3 and the conserved immunogenic epitope on gp41 could be useful in passive and active immunotherapy for the acquired immunodeficiency syndrome (AIDS).
Similar articles
- Characterization of a novel human anti-HIV-1 gp41 IgM monoclonal antibody designated clone 37.
Cao C, Bai Y, Holloway MJ, Edgeworth RL, Jackson EA Jr, Cotropia J, Ugen KE. Cao C, et al. DNA Cell Biol. 2004 Dec;23(12):836-41. doi: 10.1089/dna.2004.23.836. DNA Cell Biol. 2004. PMID: 15684710 - A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.
Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, et al. Purtscher M, et al. AIDS Res Hum Retroviruses. 1994 Dec;10(12):1651-8. doi: 10.1089/aid.1994.10.1651. AIDS Res Hum Retroviruses. 1994. PMID: 7888224 - Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41.
Viveros M, Dickey C, Cotropia JP, Gevorkian G, Larralde C, Broliden K, Levi M, Burgess A, Cao C, Weiner DB, Agadjanyan MG, Ugen KE. Viveros M, et al. Virology. 2000 Apr 25;270(1):135-45. doi: 10.1006/viro.2000.0269. Virology. 2000. PMID: 10772986 - Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. Zwick MB, et al. J Virol. 2001 Nov;75(22):10892-905. doi: 10.1128/JVI.75.22.10892-10905.2001. J Virol. 2001. PMID: 11602729 Free PMC article.
Cited by
- Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera.
Hao Y, Bai G, Wang J, Zhao L, Sutherland K, Cai J, Cao C. Hao Y, et al. BMC Immunol. 2015 Apr 28;16:25. doi: 10.1186/s12865-015-0094-z. BMC Immunol. 2015. PMID: 25927639 Free PMC article. - Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.
Diomede L, Nyoka S, Pastori C, Scotti L, Zambon A, Sherman G, Gray CM, Sarzotti-Kelsoe M, Lopalco L. Diomede L, et al. J Virol. 2012 Apr;86(8):4129-38. doi: 10.1128/JVI.06359-11. Epub 2012 Feb 1. J Virol. 2012. PMID: 22301151 Free PMC article. - Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.
Pietzsch J, Scheid JF, Mouquet H, Seaman MS, Broder CC, Nussenzweig MC. Pietzsch J, et al. J Virol. 2010 May;84(10):5032-42. doi: 10.1128/JVI.00154-10. Epub 2010 Mar 10. J Virol. 2010. PMID: 20219932 Free PMC article. - Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
Zhang MY, Vu BK, Choudhary A, Lu H, Humbert M, Ong H, Alam M, Ruprecht RM, Quinnan G, Jiang S, Montefiori DC, Mascola JR, Broder CC, Haynes BF, Dimitrov DS. Zhang MY, et al. J Virol. 2008 Jul;82(14):6869-79. doi: 10.1128/JVI.00033-08. Epub 2008 May 14. J Virol. 2008. PMID: 18480433 Free PMC article. - The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.
Montero M, van Houten NE, Wang X, Scott JK. Montero M, et al. Microbiol Mol Biol Rev. 2008 Mar;72(1):54-84, table of contents. doi: 10.1128/MMBR.00020-07. Microbiol Mol Biol Rev. 2008. PMID: 18322034 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources